Mediracer weekly updates

NEWS AND BLOG




Diabetic foot check nerve conducting testing has previously been the exclusive preserve of clinical neurophysiologists although the tests performed are not complicated. There are nerve conduction tests which need specialist skills and equipment to be performed but the testing of the responses from the nerves in the hand is simple to perform when the equipment is designed specifically for the task. Nerve conduction tests do not directly give a diagnosis. The diagnosis is always based on the symptoms and the disease history of the patient. We could compare the nerve conducting testing to testing blood pressure or measuring a patient’s body temperature.

 

DPN diabetic peripheral neuropathy test

Based on those tests it is not possible to say what causes the abnormal tests results without a clinical examination. The same goes for diagnosing diabetic foot or DPN diabetic peripheral neuropathy. When a clinical examination based on symptoms and disease history gives the indication of DPN, a nerve conduction study is then performed on medial plantar nerve. Stimulating the nerve from the big toe or hallux, the nerve response peak latencies can be compared accurately. When the nerve conduction tests findings are abnormal and it matches the clinical indications it is possible to make a reliable diagnosis of DPN and to estimate the severity. Estimating the severity of the neuropathy helps to determine the proper treatment.

 

Mediracer NCS system

When the responses from the nerve conduction tests are normal and there are symptoms indicative of another pathology. These patients need to be sent to see a specialist for further examination. The same goes for when the responses measured can’t be interpreted reliably due to a lack of clearly defined response peaks. Generally, nine out of ten diagnoses can be confirmed using Mediracer NCS system. This makes a confirmed diagnosis possible in any clinic without need to send patients away for nerve conduction studies. This saves time and money both of which are limited in today’s health care systems. This kind of Point Of Care device will be increasingly common in primary care to help streamline the patient pathway and to save money and resources, these are all important criteria for the development of primary care.

 

Mediracer Oy (Ltd)



Georg Meissner started as a CEO in Mediracer Ltd. and Head Instruments Ltd. at the end of April. Before this he has worked at Specim, Spectral Imaging Oy, as Managing Director and has lead the company successfully to a substantial growth. Prior to this he worked at Nokia in various product and program management roles, including Director of Roadmapping and Concepting.

Georg Meissner holds a Ph.D. in Chemistry from Philipps-Universität Marburg, Germany, and he is both German and Finnish national.

“Mediracer and Head Instruments are two independent companies, but this double position as CEO enables better co-operation between companies from the same business sector”, says Dr. Meissner.

Mediracer’s previous CEO Yoko Keränen will continue in the company as Business Development Director. Head Instrument’s previous CEO and co-founder Jani Katisko will continue as Specialist.

Contact Dr. Georg Meissner:

georg.meissner@mediracer.com // tel. +358 40 517 0182

Head Instruments Ltd. is Oulu, Finland, based startup developing surgical technologies. Head Instruments enables the research, clinical testing and productization of advanced surgical technologies. www.headinstruments.com

Mediracer Ltd. developes Point of Care products in the field of clinical neurophysiology for patient examinations adapted to the needs of primary health care. The target is to develop reliable and cost-effective products for examination of the most common neurophysiological disorders on primary health care level, requiring only a short training for the operators. Mediracer is part of Head Invest Group. www.mediracer.com



Georg Meissner started as a CEO in Mediracer Ltd. and Head Instruments Ltd. at the end of April. Before this he has worked at Specim, Spectral Imaging Oy, as Managing Director and has lead the company successfully to a substantial growth. Prior to this he worked at Nokia in various product and program management roles, including Director of Roadmapping and Concepting.

Georg Meissner holds a Ph.D. in Chemistry from Philipps-Universität Marburg, Germany, and he is both German and Finnish national.

“Mediracer and Head Instruments are two independent companies, but this double position as CEO enables better co-operation between companies from the same business sector”, says Dr. Meissner.

Mediracer’s previous CEO Yoko Keränen will continue in the company as Business Development Director. Head Instrument’s previous CEO and co-founder Jani Katisko will continue as Specialist.

Contact Dr. Georg Meissner:

georg.meissner@mediracer.com // tel. +358 40 517 0182

Head Instruments Ltd. is Oulu, Finland, based startup developing surgical technologies. Head Instruments enables the research, clinical testing and productization of advanced surgical technologies. www.headinstruments.com

Mediracer Ltd. developes Point of Care products in the field of clinical neurophysiology for patient examinations adapted to the needs of primary health care. The target is to develop reliable and cost-effective products for examination of the most common neurophysiological disorders on primary health care level, requiring only a short training for the operators. Mediracer is part of Head Invest Group. www.mediracer.com



Georg Meissner started as a CEO in Mediracer Ltd. and Head Instruments Ltd. at the end of April. Before this he has worked at Specim, Spectral Imaging Oy, as Managing Director and has lead the company successfully to a substantial growth. Prior to this he worked at Nokia in various product and program management roles, including Director of Roadmapping and Concepting.

Georg Meissner holds a Ph.D. in Chemistry from Philipps-Universität Marburg, Germany, and he is both German and Finnish national.

“Mediracer and Head Instruments are two independent companies, but this double position as CEO enables better co-operation between companies from the same business sector”, says Dr. Meissner.

Mediracer’s previous CEO Yoko Keränen will continue in the company as Business Development Director. Head Instrument’s previous CEO and co-founder Jani Katisko will continue as Specialist.

Contact Dr. Georg Meissner:

georg.meissner@mediracer.com // tel. +358 40 517 0182

Head Instruments Ltd. is Oulu, Finland, based startup developing surgical technologies. Head Instruments enables the research, clinical testing and productization of advanced surgical technologies. www.headinstruments.com

Mediracer Ltd. developes Point of Care products in the field of clinical neurophysiology for patient examinations adapted to the needs of primary health care. The target is to develop reliable and cost-effective products for examination of the most common neurophysiological disorders on primary health care level, requiring only a short training for the operators. Mediracer is part of Head Invest Group. www.mediracer.com






Get in touch

Contact us now

Mediracer Ltd was founded in 2002 to develop Point of Care products in the field of clinical neurophysiology for patient examinations adapted to the needs of primary health care.


Email

info@mediracer.com



Phone Number

+358 45 899 2626



Follow us

Our Activity

Provide high quality products to improve our solutions and make them more innovative to contribute to improvement of health care



Copyright by Mediracer 2019